Xenon Halts Enrollment in Depression Trials Even as FDA Filing Advances
Published on 09/18/2026 at 14:50 | Editorial boerse-global.de
Xenon Pharmaceuticals finds itself pulled in two directions at once. The biopharmaceutical company confirmed on Thursday that it has voluntarily paused new patient enrollment across its late-stage psychiatric program, while simultaneously announcing a regulatory milestone for the same drug candidate in a different therapeutic area.
The dual disclosure sent the stock reeling. Shares of the Canadian company (ISIN: CA98420N1050) were changing hands at EUR 36.40 on Friday, a daily decline of 27%. That leaves the equity roughly 42% below its 52-week high, a level it had reached during a stretch of heavy promotional activity earlier in the year.
What Triggered the Enrollment Freeze
The decision to stop screening new participants applies specifically to the ongoing Phase 3 trials in major depressive disorder (MDD) and bipolar depression (BPD). According to GlobeNewswire, management characterized the move as precautionary and voluntary. It followed a detailed review of neuropsychiatric adverse events observed during a data analysis.
Those side effects, while consistent with the mechanism of action of Xenon's lead compound azetukalner, had not surfaced in that form during the earlier Phase 2 X-NOVA study in MDD. The company is now evaluating possible adjustments to the dosing regimen.
Patients already enrolled in the studies are continuing treatment under heightened medical monitoring. The setback carries outsized weight because the psychiatry pipeline represents a central pillar of Xenon's corporate strategy. It also casts a shadow over the forthcoming X-NOVA2 readout, with topline results not expected until the first quarter of 2027.
Should investors sell immediately? Or is it worth buying Xenon?
Epilepsy Filing Offers a Counterweight
On the other side of the ledger, Xenon disclosed that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for azetukalner as a treatment for focal seizures. The filing rests on data from the Phase 2b X-TOLE trial and the Phase 3 X-TOLE2 study.
The epilepsy program appears, for now, untouched by the safety concerns that have disrupted the depression studies, since the submitted dossier draws on efficacy and safety data specific to seizure control. Xenon had already presented detailed results in this indication at the 16th European Epilepsy Congress in Athens, held September 5–9.
Azetukalner remains the company's most closely watched pipeline asset. While the NDA submission marks a step toward commercialization in epilepsy, the uncertainty surrounding the psychiatric trials is forcing market participants to reassess Xenon's growth prospects.
Balance Sheet Provides Room to Maneuver
The company is not under immediate financial pressure. As of June 30, the end of the second quarter, Xenon reported cash, cash equivalents, and marketable securities totaling USD 1,245.1 million. That quarter also brought a net loss of USD 110.7 million.
That liquidity should give management the bandwidth to investigate the root causes of the neuropsychiatric events in depth and to reshape the study strategy if needed. Investors are now focused on further FDA correspondence regarding the focal seizure application, along with any updates on when psychiatric enrollment might resume.
The release of topline data in the first quarter of 2027 remains the next major scheduled catalyst. Xenon also met with investors at the Wells Fargo Healthcare Conference on September 9, underscoring continued capital-market interest in how the story develops from here.
Ad
Xenon Stock: New Analysis - 18 September
Fresh Xenon information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
